Epithelial cancers are the most common malignancies, but immunotherapy development has been stymied because the low mutation frequency of these tumors elicits muted mutation-specific T cell responses. An NCI team has now used next-generation sequencing to identify such rare mutations in one patient and has developed an autologous cell therapy.